ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

ICOTYDE achieved high levels of complete skin clearance up to Week 52 with no new safety signals2,a "Introducing a oncedaily targeted oral peptide for treating moderatetosevere plaque psoriasis offers patients an option with a unique combination of benefits and a favorable safety profile," said Linda Stein Gold, M.D., Director of Dermatology Clinical Research at Henry Ford Health and ICONICADVANCE study investigator.c "The results from oneyear studies show encouraging outcomes for patients as they navigate ...